Sanofi agreed a multi-year collaboration with AI-driven Earendil Labs to discover and develop bispecific antibodies for autoimmune and inflammatory diseases, a partnership valued at up to $2.56 billion. Earendil will apply its predictive protein modeling and validation platform to generate bispecific candidates, while Sanofi will lead clinical development and global commercialization. The agreement includes upfront and milestone payments and tiered royalties. Earendil’s AI discovery engine and Sanofi’s development scale aim to accelerate selection of bispecifics with improved specificity. The deal underscores pharma’s continued appetite for AI-enabled discovery engines and for bispecific modalities in immunology.